---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-040936"
form_type: "8-K"
ticker: "NUVL"
cik: "0001861560"
company_name: "Nuvalent, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T19:23:18.910435+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Nuvalent Q2 net loss $29.1M; cash $431.2M; NVL-655 data expected Q4 2023

## Summary
- Net loss $29.1M ($0.51/share); R&D $25.9M, G&A $8.1M for Q2 2023.
- Cash, cash equivalents and marketable securities $431.2M as of June 30, 2023; runway into H2 2025.
- Preliminary dose-escalation data for NVL-655 from ALKOVE-1 trial expected at medical meeting in Q4 2023.
- NVL-520 ARROS-1 trial progressing toward RP2D; NVL-330 HER2 inhibitor advancing through IND-enabling studies.

## SEC filing metadata
- accession: 0000950170-23-040936
- form_type: 8-K
- ticker: NUVL
- cik: 0001861560
- company_name: Nuvalent, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1861560/000095017023040936/0000950170-23-040936-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1861560/000095017023040936/nuvl-20230810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-040936
- JSON: https://secwatch.observer/filing/0000950170-23-040936.json
- Plain text: https://secwatch.observer/filing/0000950170-23-040936.txt

## Key facts
- Earnings Releases
  Nuvalent, Inc. reported second quarter 2023 results: net income $29.1 million, or $0.51 per share.
  - Period: second quarter 2023
  - Net income: $29.1 million, or $0.51 per share
  - Result: reported results
  source text: Net loss for the second quarter of 2023 was $29.1 million, or $0.51 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1861560/000095017023040936/0000950170-23-040936-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.